Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – far from it, as signaled by the potential $2.5 billion deal signed recently ...
Glick, Ph.D., who has been with the firm since its inception in 2021 and was previously founder of IFM Therapeutics and Scorpion Therapeutics ... Foresite Capital, Logos Opportunities Fund ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $71.00. The company’s shares closed last Friday ...
In a significant move to bolster its pipeline and capabilities, Relay recently acquired Scorpion Therapeutics in a $2.5 billion cash transaction. This acquisition is viewed by analysts as a ...
IFM was a subsidiary of IFM Therapeutics, a biotech founded by Odyssey CEO Gary Glick, Ph.D. Glick previously set up and ran Scorpion Therapeutics, which Eli Lilly is now buying for up to $2.5 ...
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...
LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...
The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...
Overall, 49 patients (20 patients in Z1G and 29 in Z1H) were included in the primary efficacy analyses. The objective response rates in both cohorts were 0% (Z1G; 90% CI, 0 to 13.9) and 3.4% (Z1H; 90% ...